Thus, the presence of MMA in succinyl–coenzyme A synthase deficiency represents a highly sensitive screening test for MDDS related to SUCLA2 and SULG1 gene mutations in patients presenting with non-specific and variable neurological presentation and lactic acidosis. This evidence concerns the gene SUCLA2 and lactic acidosis.